OBJECTIVES: To correlate thyroid cancer genotype with histology and outcomes. BACKGROUND: The prognostic significance of molecular signature in thyroid cancer (TC) is undefined but can potentially change surgical management. METHODS: We reviewed a consecutive series of 1510 patients who had initial thyroidectomy for TC with routine testing for BRAF, RAS, RET/PTC, and PAX8/PPARG alterations. Histologic metastatic or recurrent TC was tracked for 6 or more months after oncologic thyroidectomy. RESULTS: Papillary thyroid cancer (PTC) was diagnosed in 97% of patients and poorly differentiated/anaplastic TC in 1.1%. Genetic alterations were detected in 1039 (70%); the most common mutations were BRAFV600E (644/1039, 62%), and RAS isoforms (323/1039, 31%). BRAFV600E-positive PTC was often conventional or tall cell variant (58%), with frequent extrathyroidal extension (51%) and lymph node metastasis (46%). Conversely, RAS-positive PTC was commonly follicular variant (87%), with infrequent extrathyroidal extension (4.6%) and lymph node metastasis (5.6%). BRAFV600E and RET/PTC-positive PTCs were histologically similar. Analogously, RAS and PAX8/PPARG-positive PTCs were histologically similar. Compared with RAS or PAX8/PPARG-positive TCs, BRAFV600E or RET/PTC-positive TCs were more often associated with stage III/IV disease (40% vs 15%, P < 0.001) and recurrence (10% vs 0.7%, P < 0.001; mean follow-up 33 ± 21 mo). Distant metastasis was highest in patients with RET/PTC-positive TC (10.8%, P = 0.02). CONCLUSIONS: In this large study of prospective mutation testing in unselected patients with TC, molecular signature was associated with distinctive phenotypes including cancers, with higher risks of both distant metastasis and early recurrence. Preoperative genotype provides valuable prognostic data to appropriately inform surgery.
OBJECTIVES: To correlate thyroid cancer genotype with histology and outcomes. BACKGROUND: The prognostic significance of molecular signature in thyroid cancer (TC) is undefined but can potentially change surgical management. METHODS: We reviewed a consecutive series of 1510 patients who had initial thyroidectomy for TC with routine testing for BRAF, RAS, RET/PTC, and PAX8/PPARG alterations. Histologic metastatic or recurrent TC was tracked for 6 or more months after oncologic thyroidectomy. RESULTS:Papillary thyroid cancer (PTC) was diagnosed in 97% of patients and poorly differentiated/anaplastic TC in 1.1%. Genetic alterations were detected in 1039 (70%); the most common mutations were BRAFV600E (644/1039, 62%), and RAS isoforms (323/1039, 31%). BRAFV600E-positive PTC was often conventional or tall cell variant (58%), with frequent extrathyroidal extension (51%) and lymph node metastasis (46%). Conversely, RAS-positive PTC was commonly follicular variant (87%), with infrequent extrathyroidal extension (4.6%) and lymph node metastasis (5.6%). BRAFV600E and RET/PTC-positive PTCs were histologically similar. Analogously, RAS and PAX8/PPARG-positive PTCs were histologically similar. Compared with RAS or PAX8/PPARG-positive TCs, BRAFV600E or RET/PTC-positive TCs were more often associated with stage III/IV disease (40% vs 15%, P < 0.001) and recurrence (10% vs 0.7%, P < 0.001; mean follow-up 33 ± 21 mo). Distant metastasis was highest in patients with RET/PTC-positive TC (10.8%, P = 0.02). CONCLUSIONS: In this large study of prospective mutation testing in unselected patients with TC, molecular signature was associated with distinctive phenotypes including cancers, with higher risks of both distant metastasis and early recurrence. Preoperative genotype provides valuable prognostic data to appropriately inform surgery.
Authors: Marisa Cañadas-Garre; Patricia Becerra-Massare; Martín López de la Torre-Casares; Jesús Villar-del Moral; Susana Céspedes-Mas; Ricardo Vílchez-Joya; Teresa Muros-de Fuentes; Carlos García-Calvente; Gonzalo Piédrola-Maroto; Miguel A López-Nevot; Rosa Montes-Ramírez; José M Llamas-Elvira Journal: Ann Surg Date: 2012-05 Impact factor: 12.969
Authors: Linwah Yip; Marina N Nikiforova; Sally E Carty; John H Yim; Michael T Stang; Mitchell J Tublin; Shane O Lebeau; Steven P Hodak; Jennifer B Ogilvie; Yuri E Nikiforov Journal: Surgery Date: 2009-12 Impact factor: 3.982
Authors: David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle Journal: Thyroid Date: 2009-11 Impact factor: 6.568
Authors: Mingzhao Xing; Ali S Alzahrani; Kathryn A Carson; Young Kee Shong; Tae Yong Kim; David Viola; Rossella Elisei; Bela Bendlová; Linwah Yip; Caterina Mian; Federica Vianello; R Michael Tuttle; Eyal Robenshtok; James A Fagin; Efisio Puxeddu; Laura Fugazzola; Agnieszka Czarniecka; Barbara Jarzab; Christine J O'Neill; Mark S Sywak; Alfred K Lam; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Hirotaka Nakayama; Roderick Clifton-Bligh; Giovanni Tallini; Elizabeth H Holt; Vlasta Sýkorová Journal: J Clin Oncol Date: 2014-10-20 Impact factor: 44.544
Authors: Lisa A Radkay; Simion I Chiosea; Raja R Seethala; Steven P Hodak; Shane O LeBeau; Linwah Yip; Kelly L McCoy; Sally E Carty; Karen E Schoedel; Marina N Nikiforova; Yuri E Nikiforov; N Paul Ohori Journal: Cancer Cytopathol Date: 2014-08-12 Impact factor: 5.284
Authors: Gina M Howell; Sally E Carty; Michaele J Armstrong; Shane O Lebeau; Steven P Hodak; Christopher Coyne; Michael T Stang; Kelly L McCoy; Marina N Nikiforova; Yuri E Nikiforov; Linwah Yip Journal: Ann Surg Oncol Date: 2011-05-19 Impact factor: 5.344
Authors: David A Kleiman; Matthew J Sporn; Toni Beninato; Michael J Crowley; Anvy Nguyen; Alessia Uccelli; Theresa Scognamiglio; Rasa Zarnegar; Thomas J Fahey Journal: Cancer Date: 2012-12-21 Impact factor: 6.860
Authors: Yuri E Nikiforov; Sally E Carty; Simon I Chiosea; Christopher Coyne; Umamaheswar Duvvuri; Robert L Ferris; William E Gooding; Steven P Hodak; Shane O LeBeau; N Paul Ohori; Raja R Seethala; Mitchell E Tublin; Linwah Yip; Marina N Nikiforova Journal: Cancer Date: 2014-09-10 Impact factor: 6.860
Authors: Nicole M Iñiguez-Ariza; Sina Jasim; Mabel M Ryder; Ashish V Chintakuntlawar; John C Morris; Crystal R Hilger; Michael E Menefee; Robert C Smallridge; Nina J Karlin; Constanza Alcaino; Keith C Bible Journal: J Clin Endocrinol Metab Date: 2020-07-01 Impact factor: 5.958
Authors: Snehal G Patel; Sally E Carty; Kelly L McCoy; N Paul Ohori; Shane O LeBeau; Raja R Seethala; Marina N Nikiforova; Yuri E Nikiforov; Linwah Yip Journal: Surgery Date: 2016-11-15 Impact factor: 3.982
Authors: Jaroslaw Jendrzejewski; Sandya Liyanarachchi; Rebecca Nagy; Leigha Senter; Paul E Wakely; Andrew Thomas; Fadi Nabhan; Huiling He; Wei Li; Krzysztof Sworczak; Matthew D Ringel; Lawrence S Kirschner; Albert de la Chapelle Journal: Thyroid Date: 2016-07-22 Impact factor: 6.568